Krystal Biotech Q2 net income rises 43% to $54.8 million; revenue climbs 24% to $119.2 million

• Krystal Biotech posted 2Q net income of $54.8 million, or $1.79 per diluted share, up from $38.3 million a year earlier.
• Product revenue rose 24% year over year to $119.2 million, with gross margin at 95%.
• Cash and investments totaled $1.1 billion at quarter-end; FY 2026 non-GAAP R&D and SG&A expense guidance was $175 million-$195 million.
• VYJUVEK logged $965.9 million in global revenue since launch, with more than 730 reimbursement approvals and over 640 unique U.S. prescribers.
• Management flagged multiple clinical readouts in 2H 2026; VYJUVEK launches in Spain and Italy remain targeted before year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802189) on August 03, 2026, and is solely responsible for the information contained therein.